BHIVA guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update)
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of women living with HIV in the UK during pregnancy and postpartum, and their infants. The scope includes guidance on the use of antiretroviral therapy (ART) both to prevent vertical transmission of HIV and for the welfare of the woman and her baby, guidance on mode of delivery and recommendations in specific patient populations where other factors need to be taken into consideration, such as co-infection with other agents.
The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of pregnant women living with HIV. The 2018 guidelines have identified significant developments that have either led to a change in recommendation or a change in the strength of recommendation. More detail has been added in areas of controversy, particularly breastfeeding. New data that simply support the existing data have not routinely been included in this revision. A new section on the postpartum management of women has been added. Of note, the term ‘HIV’ refers to HIV-1 throughout these guidelines, unless HIV-2 is specified.
The purpose of a further 2020 interim review is to update significant developments that would either lead to a change in recommendation or a change in the strength of recommendation. These changes and the supporting evidence are highlighted. Additional information has been provided in areas of controversy.
Read full guidelines